Saturday 17 October 2026
Export FLGT’s income statement to Excel — free account
Fulgent Genetics, Inc.
FLGT Healthcare Diagnostics & Research
Fulgent Genetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $322.7 million, up 13.8% from fiscal 2024. In the quarter to June 2026, revenue grew 4.38%, EPS fell 69.4% and free cash flow grew 25.4%, each against the same quarter a year earlier.
19.81
1.53
−7.17%
Follow FLGT
Fulgent Genetics, Inc. (FLGT) P/E ratio
Fulgent Genetics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 402× (August 2020) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 6.5× | 11.55% |
| FY2021 | 5.8× | (2.74%) |
| FY2020 | 6.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 39 more quarters | Free account |
Against its own ten years
Low 0.0×
High 402×
Ten-year median
0.0×
Current reading's percentile
73
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| WGS GeneDx Holdings Corp. compare | n/m |
| CSTL Castle Biosciences, Inc. compare | n/m |
| NEO NeoGenomics, Inc. compare | n/m |
| MYGN Myriad Genetics, Inc. compare | n/m |
| BDSX Biodesix, Inc. compare | n/m |
| FLGT Fulgent Genetics, Inc. | n/m |
| XGN Exagen Inc. compare | n/m |
| PSNL Personalis, Inc. compare | n/m |
| OPK OPKO Health, Inc. compare | n/m |
| Diagnostics & Research industry median | 35.6× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)